Max Robotics — Global Service Robot Directory + US Certification

About

Richard A. Gardner is a prominent analytical biochemist whose research sits at the intersection of glycomics, biopharmaceutical science, and disease biomarker discovery. His work has made significant contributions to advancing the tools and methodologies that underpin our understanding of protein glycosylation — the complex sugar modifications that influence biological function and disease. Gardner's most influential contribution, a 2014 review on high-throughput glycomics analysis (83 citations), helped define the landscape of automated analytical technologies for characterizing glycoprotein glycosylation, with implications for both drug development and clinical diagnostics. Building on this foundation, his 2019 study introduced a semi-automated workflow for O-glycosylation analysis, reflecting his commitment to improving throughput and reproducibility in glycoproteomic research. His methodological rigor is further evident in work validating serum N-glycan profiling protocols under varied experimental conditions, ensuring the reliability of glycan biomarkers for disease detection. More recently, Gardner has turned attention to automating immunoglobulin glycosylation analysis, a growing area in personalized medicine. Across his career, Gardner's research has empowered the broader scientific community to pursue glycan-based diagnostics and biopharmaceutical characterization with greater efficiency and confidence.